All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

Merck KGaA and Remepy join forces to develop combo drug-digital therapies

Merck KGaA has inked a collaboration deal with Israeli-US startup, Remepy, to explore the therapeutic potential of combination drug and…
HRS 2026: Medtronic, Boston Scientific and Abbott debut key PFA data

Boston Scientific, Abbott and Medtronic all presented successful readouts of their cardiac devices during the Heart Rhythm Society’s (HRS) 2026…
Roche builds MRD testing arsenal in $595m Saga Diagnostics buyout

Roche has agreed to acquire molecular residual disease (MRD) specialist, Saga Diagnostics and its platform in a $595m bid –…
Biomarker-led trials to guide the future of precision psychiatry

As the neuroscience treatment landscape continuously evolves towards the wider use of precision treatment options, biomarker-led trials are emerging as…
Boehringer hands over $50m and market rights for Click’s digital therapeutic

Boehringer Ingelheim and Click Therapeutics have shifted the dynamic of their long-term collaboration, which will see Click take the commercialisation…

Tempus’ automated alerts boost patient outcomes in valvular heart disease

Tempus and Medtronic have uncovered the potential of artificial intelligence (AI)-driven electronic clinician notifications (ECNs) in improving outcomes and supporting…
Medtronic’s OmniaSecure defib lead nets another FDA approval

Irish medtech giant Medtronic has secured another US approval for its OmniaSecure defibrillation lead, expanding its use to placement in…
Vinay Prasad to leave the FDA again

Vinay Prasad is once again set to depart from his role at the US Food and Drug Administration (FDA), after…
Daiichi and GAIA join forces to commercialise digital cardiovascular therapy

Daiichi Sankyo’s European faction and health technology company GAIA have banded together to commercialise a digital therapeutic designed to support…
Polares secures $50m in Series C to advance mitral transcatheter

Polares Medical has secured $50m through a Series C financing round to further support the development of its novel cardiac…